



Cagrilintide, developed under the code AM833, is a synthetic analog of amylin, the hormone the pancreas co-secretes with insulin after a meal. A fatty-acid chain attached through a glutamate spacer lets it bind albumin, which is why its measured half-life runs to roughly 159 to 195 hours where native amylin clears in minutes. Receptor pharmacology work across 25 endpoints characterized it as a non-selective agonist of the calcitonin receptor family, meaning it activates the amylin receptors built from the calcitonin receptor plus receptor activity-modifying proteins as well as the calcitonin receptor on its own, with a binding and regulation profile distinct from selective analogs such as pramlintide. Published trials have measured body weight, glycemic parameters and gastrointestinal tolerability, both alone and co-administered with GLP-1S. Those data come from the sponsor's investigational drug product, not from research material.
Structured specifications and handling data
Technical specifications
Lys-Cys-Asn-Thr-Ala-Thr-Cys-Ala-Thr-Gln-Arg-Leu-Ala-Glu-Phe-Leu-Arg-His-Ser-Ser-Asn-Asn-Phe-Gly-Pro-Ile-Leu-Pro-Pro-Thr-Asn-Val-Gly-Ser-Asn-Thr-Pro-NH2 (cyclic Cys2-Cys7 disulfide; N-terminal gamma-Glu spacer carrying a C20 diacid)C194H312N54O59S2Stability and handling
Compounds commonly studied alongside this one.
Amylin receptors are not single proteins. They are built from the calcitonin receptor paired with one of the receptor activity-modifying proteins, and which RAMP is present changes what the receptor responds to. Cagrilintide was profiled against that whole family and turned out to be non-selective: it activates the amylin receptors and the calcitonin receptor alone, which separates it from amylin-selective analogs like pramlintide. The comparison across 25 binding, activation and receptor-regulation endpoints is the clearest published account of what the molecule actually does at the receptor.
The other half of the design is exposure. A fatty-acid chain attached through a glutamate spacer binds albumin, and measured half-life in a phase 1b trial ran 159 to 195 hours with time to peak concentration between 24 and 72 hours. Native amylin clears far too fast for that kind of experiment, so this is what makes sustained amylin-receptor activation a question a study can ask at all.
The pathway sits alongside incretin signaling rather than inside it, which is why much of the published work co-administers cagrilintide with GLP-1S. In the phase 1b combination trial, exposure was proportional to cagrilintide amount and did not affect GLP-1S exposure or elimination, so the two can be varied independently. Reported adverse events in these trials were predominantly gastrointestinal, and nausea rates in the phase 2 monotherapy trial ran 20% to 47% across amounts against 18% on placebo.
Published studies and concise summaries for research review.
AI-generated summary of this research paper below.
Concise answers about laboratory context, handling, and documentation for this compound.
Laboratory compliance notice
All compounds sold by Validated Peptides are intended for in-vitro laboratory research only.
These materials are not approved by the FDA for human or animal use and are not intended for diagnostic, therapeutic, or clinical applications.
Purchasers are responsible for compliant handling, storage, and use within an appropriate laboratory environment.